Please provide the timestamps for the one-minute intervals you'd like highlighted. The transcript is currently formatted with timestamps in milliseconds. I need the minute markers (e.g., 0:00, 1:00, 2:00, etc.) to extract the relevant excerpts.
This Finding Genius podcast episode features Mike Kelly, CEO of NervGen Pharma, discussing their work on nervous system repair, specifically spinal cord injury repair. The interview explores NervGen's technology, clinical trials, and the potential for a breakthrough in treating spinal cord injuries.
The conclusion of the video is that NervGen Pharma is conducting a Phase 1B/2A clinical trial for their drug MVG291, aimed at treating spinal cord injuries. Results from the chronic injury cohort are expected in early June, with the subacute cohort results following sometime in 2025. The success of this trial hinges on demonstrating a correlation between improved nerve signaling (measured by electrophysiology) and functional improvements in patients. If successful, this could lead to a breakthrough in spinal cord injury treatment and a fast track to FDA approval. The drug appears to have minimal side effects and is administered via subcutaneous injection. Patients will likely access the treatment through physical rehabilitation physicians if and when the drug gains FDA approval.
